[PDF] Top 20 Algoritmo evolutivo diferencial aplicado al problema de despacho hidrotérmico

... for ranibizumab therapy at Moorfields Eye ...for ranibizumab funding were made if the lesion character- istics and visual acuity of the eye being considered for treatment fulfilled the inclusion and ... See full document

... The study was explorative, and all the analyses are descrip- tive. The mean change in visual acuity over the 2-year period was calculated for patients who received one or more doses of ranibizumab treatment and ... See full document

... with clinical audits from each center indicating equivalent treatment ...monthly ranibizumab therapy for 3 months followed by 4–6 weekly review and pro-re-nata ...a macular scan using optical ... See full document

... the ranibizumab group (weighted mean difference: ...and ranibizumab therapy with respect to unchanged or recurrent leakage of choroidal neovascularization (OR: ...central macular thickness ... See full document

... Defining the proportion of reduced responders in the MARINA and ANCHOR trials is not entirely possible, as both report the proportion of patients improving by more than 15 letters, and the primary end point was the ... See full document

... of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious ...with macular edema have been treated by DEX implant, including ... See full document

... This was a consecutive, retrospective, observational study to assess visual outcomes in treatment-experienced patients with nAMD who were treated with aflibercept in accordance with the drug label. The study was ... See full document

... the initial visual acuity or the lesion ...percent- age of patients who achieve 20/40 vision or better, because that level of vision is suffi cient for reading reasonably sized ...the ranibizumab ... See full document

... Ranibizumab and Bevacizumab have been in use for nAMD for some time, with Aflibercept being introduced later [5, 6]. Switching of treatment to Aflibercept was attempted in patients who were either unresponsive or ... See full document

... beam therapy, using a technique called stereotactic radiotherapy or ...beam therapy by d ividing the dose into several separate beams that pass into the eye via different locations on the ... See full document

... Anti-VEGF therapy helps to keep the VA stable for a period of time, but cannot totally stop the progression of the disease ...of neovascular AMD can maintain VA even if they are relatively ... See full document

... Epiretinal Therapy (CABER- NET) trial was a large, pivotal, multicenter, randomized controlled trial investigating the use of EMB in 495 treatment naïve ...anti-VEGF therapy in the radiation arm, as this ... See full document

... Neovascular AMD was diagnosed in patients who were older than 50 and showed exudative changes from chor- oidal neovascularization (CNV) on fluorescein angiography (FA) and SD-OCT. This study excluded cases of ... See full document

... receiving ranibizumab alone and 29 receiving combined treatment. The average age was ...the ranibizumab alone group and ...the ranibizumab alone group improved from ...the ranibizumab ... See full document

... to ranibizumab and were switched to aflibercept (AF group), 8 patients who received ranibizumab and photody- namic therapy (PDT group), and 13 patients who responded to ranibizumab (control ... See full document

... standardized clinical environment, the way of patient work-up and follow-up is less intensive as in many stud- ies but follows the laws of standard ...in clinical trials as possibly observed in daily ... See full document

... of ranibizumab for neovascular age-related macular degeneration, which included an independent economic evaluation ...a ranibizumab injection, which, when converted to US ... See full document

... Participants in both groups received an initial loading phase of 3 monthly IVR. Retreatment criteria for further injections performed by a masked examiner were as follows: 1) any intraretinal or subretinal fluid ... See full document

... acuity gradually decreased during long-term follow-up with retreatment using a pro re nata regimen when patients exited from the MARINA or ANCHOR trial. These findings indi- cated that anti-VEGF therapy is a long ... See full document

... with ranibizumab and had satisfactory visual ...that macular dryness ranged from dry to slightly ...from initial examination (days) as explanatory variables and patients as clusters revealed that CMT ... See full document